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Abstract
The accurate genotyping of human papillomavirus (HPV) is clinically important because the oncogenic potential of HPV is
dependent on specific genotypes. Here, we described the development of a bead-based multiplex HPV genotyping (MPG)
method which is able to detect 20 types of HPV (15 high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68
and 5 low-risk HPV types 6, 11, 40, 55, 70) and evaluated its accuracy with sequencing. A total of 890 clinical samples were
studied. Among these samples, 484 were HPV positive and 406 were HPV negative by consensus primer (PGMY09/11)
directed PCR. The genotyping of 484 HPV positive samples was carried out by the bead-based MPG method. The accuracy
was 93.5% (95% CI, 91.0–96.0), 80.1% (95% CI, 72.3–87.9) for single and multiple infections, respectively, while a complete
type mismatch was observed only in one sample. The MPG method indiscriminately detected dysplasia of several
cytological grades including 71.8% (95% CI, 61.5–82.3) of ASCUS (atypical squamous cells of undetermined significance) and
more specific for high grade lesions. For women with HSIL (high grade squamous intraepithelial lesion) and SCC diagnosis,
32 women showed a PPV (positive predictive value) of 77.3% (95% CI, 64.8–89.8). Among women .40 years of age, 22
women with histological cervical cancer lesions showed a PPV of 88% (95% CI, 75.3–100). Of the highest risk HPV types
including HPV-16, 18 and 31 positive women of the same age groups, 34 women with histological cervical cancer lesions
showed a PPV of 77.3% (95% CI, 65.0–89.6). Taken together, the bead-based MPG method could successfully detect high-
grade lesions and high-risk HPV types with a high degree of accuracy in clinical samples.
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Introduction
Human papillomavirus (HPV) infection is associated with a
variety of clinical conditions, ranging from asymptomatic
infections to benign and malignant diseases of the genital mucosa
[1]. In the only extensively studied host, humans, nearly 100 HPV
types have been described based on the isolation of the complete
genome [2]. The HPV types have been grouped into high risk and
low risk HPV types according to their potential to cause invasive
cancer [3]. Studies of the oncogenic potential of HPVs have
clearly demonstrated that high risk HPVs are a necessary cause for
the development of cervical cancer [4].
There are currently two main molecular approaches used for
HPV detection: the polymerase chain reaction (PCR) with generic
primers used to amplify part of the L1 gene of the viral capsid,
which is highly conserved among anogenital HPVs, and the
Hybrid Capture II test (HCII; Digene, Gaithersburg, MD, USA),
which detects 13 high risk HPVs including 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59 and 68. The HCII allows quantification of
the HPV DNA load, but lacks information on the HPV genotype.
Since the oncogenic potential differs among the high risk HPV
types [5–7], viral genotyping, following high risk HPV detection,
might be useful for better risk stratification of high risk positive
women. The general PCR-based methods followed by PGMY line
blot [8] and LiPA line blot [9], targeting the L1 region of the HPV
genome, enable the precise identification of the HPV genotypes
present in samples. However, these assays are restricted to a
maximum of about 40 oligonucleotide probes per hybridization
reaction due to the format of the line blot strips and depend on a
visual read-out of the signal [10]. In addition, none of these assays
can be automated or deployed on a high-throughput platform,
features that are essential for an assay intended for use with a large
volume of patients.
Luminex (xMAP) suspension array technology is based on
polystyrene beads that are internally dyed with various ratios of
two spectrally distinct fluorophores. Different molecules such as
individual oligonucleotide probes can be coupled to different bead
sets with specific absorption spectra. These sets are combined to a
suspension array and allow up to 100 different probes to be
measured simultaneously in a single reaction (multiplexing). This
technology can potentially be fully automated, dramatically
decreasing the personal cost component of the assay; this assay
has been used for the genotyping of 45 HPV types with PGMY09/
11 PCR [11], 22 HPV types with GP5+/6+ PCR [10], 15 HPV
types with YBT L1/GP-1 PCR [12], and 18 HPV types with
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methods have been compared with other well established HPV
detection methods such as HCII, restriction fragment length
polymorphism [14] and DNA chip technology [15] for the
evaluation of their performance. However, none of these well
established assays are perfect and suitable for the ‘‘gold standard’’.
Sequencing gives the most conclusive genotype information,
although it is the most labor intensive [16,17]. However,
sequencing is the most desirable way to validate HPV genotyping
methods.
The purpose of the present study was to validate a bead-based
MPG method developed for the identification of 20 HPVs (15 high
risk HPV types including 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56,
58, 59, 66, 68 and 5 low risk HPV types including 6, 11, 40, 55,
70) with sequencing. Histologically confirmed cervical intraepi-
thelial neoplasia (CIN) grade 1 (CIN1), and CIN grades 2–3 or
higher (CIN2+) were used. This study showed that the MPG
method is a valuable tool for the detection of pre-cervical cancer or
cervical cancer lesions (CIN2+).
Results
All women underwent cytologic testing and HPV screening.
The number of sequencing positive and negative samples was 484
and 406, respectively. Among these, 484 PCR product positive
samples were used for the evaluation of the bead-based MPG
method as shown in Figure 1A. Among 484 women with HPV
infections were 339 controls with negative histology including
cervicitis, 32 women with histologically confirmed cervical
intraepithelial neoplasia (CIN) grade 1 (CIN1), and 113 women
with histologically confirmed CIN grades 2–3 or higher (CIN2+).
Sensitivity and specificity of the bead-based MPG
method
The bead-based MPG method basically uses the MFI of the
reporter fluorescence for HPV genotyping. That is, positivity of
the respective types is calculated from the MFI over a defined
cutoff value and can provide a semi-quantitative numerical output.
For the calculation of the cutoff value, the biotinylated PGMY09/
11 amplimers generated from 200 ng of the HPV negative human
DNA were hybridized after one step PCR (see Materials and
Methods for detail). The background value was in the range from
50 MFI to 135 MFI depending on the HPV probes used (Table
S1). The detection limits were determined by using HPV plasmids
with serial dilution based on the cutoff value of 150 MFI as shown
in Figure 1B. The bead-based MPG method successfully detected
HPV 16 at 50 plasmid copies while HPV 40 was detected even at
five plasmid copies. Less than five thousand plasmids were
sufficient for the detection of all 20 HPV types using one step
reaction.
To determine the ability of the bead-based MPG method to
specifically detect different HPV types, the 20 type-specific probes
and the GAPDH probe were coupled individually to defined bead
sets (‘‘21-plex’’) and hybridized to PMGY09/11 amplicons
generated from 1610
6 copies of HPV plasmids and 200 ng of
genomic DNA from HeLa cells known to be HPV 18 positive.
Positivity for the respective types was calculated from the MFI
over their cutoff values. The PGMY09/11 PCR amplicons of the
HeLa cells showed a high MFI value only in for the HPV 18
probe. There was a 10 fold higher MFI for GAPDH than the
other PGMY09/11 PCR amplicons without GAPDH genomic
DNA (Table 1). In addition, no significant cross-hybridization
signals were generated by the PCR amplicons of individual HPV
plasmids. These findings indicate good discrimination with the one
step PCR product generated by the biotinylated PGMY09/11
primers.
Analysis of clinical samples and comparison with
Sequencing
As shown in Figure 1C, the performance of the bead-based
MPG was tested on 484 clinical samples that were PGMY09/11
PCR product positive and the accuracy was verified by
sequencing. The bead-based method detected 383 single infections
and 101 multiple infections. For the single infections, the 16 HPV
genotypes including HPV-6, 11, 18, 31, 35, 40, 45, 56, 59, 66, and
70 showed 100% accuracy while the lowest accuracy (55.6%) was
observed for HPV 68 (Table 2). The accuracy for HPV-16, the
most common HPV type, was 98.1% even with its high number of
samples compared to the other HPV types. The other common
single infections were HPV-18, HVP-53 and HPV-58, and the
accuracies of these types were 100%, 81.6%, and 87.1%,
respectively.
The accuracy of the bead-based MPG method was also
estimated for multiple infections (Table S2). The verification of
multiple infections was performed by sequencing with the
respective type-specific primer. Eighty percent of the total of
multiple infections showed a perfect match while a complete type
mismatch was observed only in one sample. The double infections
containing HPV-16 and 18 accounted for 37.6% of the total
number of multiple infections. The double infections containing
only low risk HPV types were found in only 5.5% of the samples.
The MPG method indiscriminately detected dysplasia of several
grade cytology including 71.8% of ASCUS (atypical squamous
cells of undetermined significance) and more specific for high
grade lesions as shown in Table 3. Of the total women with a
positive HPV result and a histological diagnosis (n=271) including
all age groups, 90 women had histological cervical cancer lesions
(CIN2+), giving a PPV of 32.3%. For women with HSIL and SCC
diagnosis, 32 of 43 women having histological CIN2+ showed a
PPV of 74.4%. Among women .40 years of age, the data showed
that 22 of 25 women with the same histology showed a PPV of
88%. Of the highest risk HPV types including HPV-16, 18 and 31
positive women of all age groups, 62 of 88 women had a diagnosis
of CIN2+, giving a PPV of 70.4% as shown in Table 4. Among
women .40 years of age, 34 of 44 women with the same histology
showed a PPV of 77.3% (Table 5). This result suggests that with a
higher PPV of the test and high-grade histological diagnosis, the
MPG method is an important tool in detecting women with the
high-grade lesions or high risk HPV types.
The HPV genotyping by the bead-based method and
sequencing showed almost perfect agreement (k=0.935; 95%
CI, 0.91–0.96); while the k values for the detection of HPV 16 and
18 were 0.99 and 0.96, respectively. In addition, the sensitivity,
specificity and accuracy of the bead-based MPG method were
90.7%, 100%, and 94.9%, respectively, for the detection of high
risk HPVs when the genotype information given by sequencing
was used as the standard. This suggests that the bead-based MPG
method could successfully detect HPV infections and identify HPV
genotypes with a high degree of accuracy.
Discussion
Accurate HPV genotyping has become an important prognostic
indicator in the clinical screening of women due to the strong
casual relationship between persistent HPV infection and high
grade cervical intraepithelial neoplasia [18,19]. In cervical
screening programs, HPV DNA is typically detected by a non-
radioactive signal amplification method, the Hybrid Capture II
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the detection of 13 probable high risk and five low risk HPV types
using two different cocktails of RNA probes, in two reactions [20].
HC2 is at present the only Food and Drug Administration-
approved assay for routine detection of HPV infections [21]. The
HC2 assay provides information on the viral load, which is useful
in detecting recurrences after treatment of cervical intraepithelial
neoplasia 3 and micro-invasive cancer as well as the response to
radiation therapy for cervical cancer [22,23]. However, the HC2
does not provide information on the specific type of HPV detected.
In addition, it is less sensitive than the PCR-based method and the
cross-reactivity of the two cocktail probes decreases the clinical
specificity of a positive result [20]. The sensitivity and the
specificity of HPV DNA can be improved by PCR-based methods
including restriction fragment length polymorphism (RFLP)
assays, reverse hybridization analysis, microarray platforms and/
or sequencing. Among these methods, sequencing is the ‘‘gold
standard’’ for HPV genotyping, in which HPV DNA is amplified
with primers such as GP5+/6+ (consensus) or MY09/11
(degenerate) followed by sequencing. Since the HPV genotyping
by sequencing is the most accurate method, it is desirable to
evaluate the accuracy of any HPV genotyping method on the basis
of the sequencing results [16,17]. In this study, the one step PCR
product generated by the biotinylated PGMY09/11 primer
showed good discrimination for 484 HPV positive samples and
evaluated by sequencing. The accuracy of the MPG method was
93.5% (95% CI, 91.0–96.0) and 80.1% (95% CI, 72.3–87.9) for
single and multiple infections, respectively. This indicates that the
HPV genotype of clinical samples could be successfully identified
by the bead-based MPG method with a high degree of accuracy
and one step reaction.
In most studies, the HPV genotyping accuracy in multiple
infections has not been evaluated because the conventional direct
sequencing cannot resolve the identity of genotypes in samples
containing multiple infections in which viral sequences overlap
[16,24,25]. Recent study showed that sequencing was able to
identify types in only four cases of multiple infection, which were
those having only two virus types in the sample [26]. In the
multiple infection, the sequencing yields nonspecific amplification
products, which causes nonspecific and uninterruptible sequencing
data. Therefore, it was suggested that both sequencing and type-
specific PCR could be employed as a genotyping strategy for HPV
Figure 1. Overall scheme of multiplex bead-based assay and its representative multiplexing results. A) Assay workflow of a bead-based
multiplex HPV genotyping (MPG) method showing the general steps required to detect 20 types of HPV. B) Standard curves for the multiplexed HPV
genotyping assays in a 96-well microplate format results. The detection limits were determined by using HPV plasmids with serial dilution based on
the cutoff value of 150 MFI. C) Dot plot obtained from microspheres encoded with intensities of two fluorochromes. The number is for each type of
HPV. The white circles represent each bead type’s spectral address; a flow cytometer classifies the bead type and amount of PCR product attached to
each bead’s surface, expressed as MFI. The sample injection volume was 50 ul, and the system was set to count 100 events for each of the color-
coded beads. While the Luminex beads fall within their respective regions for detection and counting, the larger particles fall near the bottom of the
graph, and do not interfere with Luminex particle detection and counting. Increasing density is indicated by contrasting colors.
doi:10.1371/journal.pone.0032259.g001
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confirmed by repeated sequencing analysis with type-specific
primers. The high accuracy of the bead-based MPG method in
multiple infections might be due to the efficient hybridization
kinetics of Luminex suspension array, which closely approximates
the kinetics of solution-phase hybridization [11] and results in
short hybridization times and faster turn-around times that is
possible with the DNA chip. In addition, the quality of the bead-
based MPG method is more controllable than with the DNA chip;
this is because its performance can be tested by sampling the
master array of beads.
This study also showed that 89.3% (95% CI, 86.2–92.4) of
single infections were caused by high risk types; the three main
high risk types were HPV-16, 18, and 53. In the contrast to other
studies [15,27], the frequency of HPV-53 was as high as HPV-18.
This suggests that HPV-53 might also play an important role in
the development of cervical cancer in Korean women. Studies of
sequential HPV acquisition have shown that co-infection is
common and most women experience multiple infections over
time [28,29]. Multiple infections in the present study accounted for
20.9% (95% CI, 14.2–27.6) of all HPV infections. Ninety five
percent of double infections carry at least one high risk type of
HPV and 15% of them occurred within the same subgroup, A7,
including HPV-16, 31, 33, 35, 52, and 58. HPV-16 was most
frequently detected in double infections. This supports the findings
that preexisting HPV-16 was generally associated with an
increased risk for subsequent acquisition of other HPV genotypes
(both phylogenetically related and unrelated) [30]. All of multiple
infections contain at least one high risk type while 39% of them
carry only high risk types. It was shown that the risk of co-infection
was higher for types 6, 11, 16, 18, 31, 33, 51, 52, and 56 where all
types except for types 6 and 11 are high risk HPV [31]. This
indicates that the high risk type of HPV might play an important
role in multiple infections. Multiple infections might carry a lower
risk for malignant progression than single infections with high risk
types of HPV, due to the suppressive effect of E2 protein by a type
of HPV on E6 and E7 ORFs of another type HPV; because a
significantly higher proportion of double infections were detected
in women with normal or inflamed cervices than among women
with cervical intraepithelial neoplasia 1 or higher severity [32].
However, the number of HPV types showed a significant
relationship with the PPV of the cervical intraepithelial neoplasia
grade. Of the highest risk HPV types including HPV-16, 18 and
31 positive women .40 years of age, 34 of 44 women with
histology had a diagnosis of CIN2+, giving a PPV of 77.3% (95%
CI, 65.0–89.6). (70.4% for women of all age). In this case, HPV 16
positive women have a PPV for CIN2+ of 80.6% (95% CI, 66.7–
94.6), suggesting that HPV 16 positive women can get a better
clinical safety by direct treatment.
In this study, such relationships with multiple infections and
cervical intraepithelial neoplasia grade were also observed. The
PPV for HPV positive women with ASCUS is higher than the
PPV for women with normal cytology, indicating that the
consistency might be due to the high accuracy of the bead-based
genotyping method with enough sample numbers. Among women
.40 years of age, the PPV of the diagnoses HSIL and SCC for
CIN2+ were 93.3% and 80.0% respectively. This suggests that
women .40 years of age with HSIL and a positive HPV test can
be directly referred to treatment. HPV 16 positive women have a
PPV for CIN2+ of 78.1% when including all age groups,
Table 1. Type specificity of the bead-based MPG method.
20 HPV type and
HeLa cells GAPDH probe and HPV type-specific probe
GAPDH 6 11 16 18 31 33 35 39 40 45 51 52 53 55 56 58 59 66 68 70
HeLa 96 10 21 12 6650 15 14 18.5 17 88 15 8 20 22 19 10 14.5 28.5 24 19 22
6 14 5194 73 40 36 18 38 93.5 73 52 40 16 25.5 73 40.5 29 47 105.5 37.5 72 42.5
11 7 9 4079 24 12.5 11.5 17.5 55 33 35 20 9 12.5 37.5 30 16 23 48 18.5 30.5 34.5
16 6 6.5 18 4781 13 12 15 21.5 19 19 13 9 12 16.5 11 9 14 29 12 20 12
18 6 9 16 15.5 5751 10 12 30 24 17 11 6 10.5 18 11 9 13 31 10.5 19 14
31 7.5 10 19.5 20 9.5 2623 13 26 22 18 10 8 12 20 11 10 15 35.5 14 24 13
33 5 7 15 21.5 15 11.5 4903 28.5 21 18 12.5 6.5 11.5 23.5 13 9 15 37 14.5 20 14
35 8 11 27 26.5 15 15 21 6456 34 22.5 17 8.5 13 32 19 13 17 68 24 31 19
39 10 13 27 30.5 12 13 20 44.5 2961 20 21 10 18 37 20.5 12 22.5 53 21 36 22.5
40 8 8 20.5 20 11.5 13 17.5 34.5 28 7172 18 8 15.5 24 19 11 21 45 15.5 26 19
45 6.5 6 18 22 11.5 9 11 21 23 82 3598 7 8 14 13 10 9 33 14 17 11
51 7 8 18 18 13 11 9 27 17.5 20 8 6449 13 19 11 9 12 42.5 15 15 14
52 5 9 14 16 10 10.5 9 22 17 91 12 5 1485 21 10 7 10 32 10 14.5 13
53 5 8 17 21 8 14 11 23 19 85 11 4 13 4631 10 8 11.5 31 12 22 12
55 7 9 19 21 8 10 14 26 27 18 14 8 12 23 2536 10 14 41 12 25 15
5 6 8 8 1 3 1 6 9991 9 1 6 . 5 1 4 951 0 1 3 64 4 4 3 1 1 2 6 . 5 1 2 1 8 9
58 3.5 9 24 14 11 13 14 34 39 138 15 8 12 27 14.5 10 2535 48 18.5 30 15
59 5 6 12 12 7 10 8 46 14 11 9.5 7 12 14 8 8 8 5457 11 15.5 8
66 9 8 17 15 10 14 15 22 20 19 9 7 11 17.5 8 9 16 28 2007 20 11
6 8 3 6 1 2 1 2 7 . 5 1 0 1 0 1 8 1 7 5 1 9581 5 7 . 5 692 4 1 0 5 7 7 1 9
7 0 9 1 6 2 61 51 41 81 73 93 21 41 73 1 32 61 11 01 25 21 7 . 5 3 05 3 2 5
doi:10.1371/journal.pone.0032259.t001
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diagnosis, while the PPV of the other HPV types is lower. Thus,
these findings suggest that the bead-based MPG method showed a
higher clinical specificity and positive predictive value, specially for
CIN2+. For the fundamental understanding of multiple infections
and patient follow up for CIN2+ [33], the specific biological
features of individual HPV types such as integration status and
RNA expression, might be also needed [34]. In addition, a study
on the interaction among different HPV types is necessary for
achieving better understanding of multiple infections. HPV-HPV
interactions might occur through indirect interactions that result
from alterations of the host environment or immunological
interactions in addition to the direct interactions of HPV genes
or gene products.
The accurate genotyping of human papillomavirus is clinically
important because the oncogenic activity of HPV is dependent on
the specific genotypes. Although HPV genotyping by sequencing is
the most accurate method, it is the most labor intensive and time-
consuming. Therefore, the ideal HPV genotyping method should
have genotyping accuracy comparable to sequencing and be
automated or deployed on a high-throughput platform, features
essential for an assay intended for a large volume of patients. Our
findings suggest that the bead-base MPG method is a valuable
strategy for an efficient HPV genotyping and risk stratification of
women with a positive HPV test.
Materials and Methods
Ethics statement
All patients involved in the study had signed a declaration of
consent stating that the patients specimens may be used for
scientific intentions. Specimens were obtained from the patients in
the Department of Obstetrics and Gynecology in concordance
with procedures approved by the Institutional Review Board of
The Catholic University of Korea (07BR238).
Table 2. The accuracy of the bead-based MPG method in
single infections.
HPV
genotype
No. of positive
samples
with bead-
base MPG
No. of samples
confirmed by
sequencing Accuracy (%)
6 13 13 100.0
11 4 4 100.0
16 105 103 98.1
18 31 31 100.0
31 15 15 100.0
33 7 6 85.7
35 10 10 100.0
39 16 15 93.8
40 2 2 100.0
45 3 3 100.0
51 19 16 84.2
52 25 23 92.0
53 38 31 81.6
55 4 3 75.0
56 20 20 100.0
58 31 27 87.1
59 4 4 100.0
66 9 9 100.0
68 9 5 55.6
70 18 18 100.0
Total number 383 358 93.5
doi:10.1371/journal.pone.0032259.t002
Table 3. Total women with a positive HPV test and a histological diagnosis.
Cytology
Total with this
diagnosis HPV positives
Women with CIN2+ among
the HPV positives
Women with a histology
diagnosis PPV for CIN2+ (95% CI)
Normal 222 94 27 115 23.4 (15.6–31.1)
ASCUS 71 51 15 46 32.6 (19.1–46.1)
LSIL 88 80 16 74 21.6 (12.2–310)
HSIL 32 32 20 29 68.9 (52.1–85.7)
SCC 15 14 12 14 85.7 (67.4–100.0)
Total 428 271 90 278 32.3 (26.8–37.8)
Women .40 years of age
Normal 90 42 14 59 23.7 (12.8–34.6)
ASCUS 40 28 8 25 32.0 (13.7–50.3)
LSIL 38 36 5 36 13.8 (2.53–25.1)
HSIL 20 20 14 15 93.3 (80.65–100.0)
SCC 10 9 8 10 80.0 (55.2–100.0)
Total 198 135 49 145 33.8 (24.7–39.9)
ASCUS, atypical squamous cells of undetermined significance.
LSIL, low grade squamous intraepithelial lesion.
HSIL, high grade squamous intraepithelial lesion.
SCC, squamous cell cervical carcinoma.
CIN2+, higher cervical intraepithelial neoplasia.
doi:10.1371/journal.pone.0032259.t003
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A total of 890 cervical samples were tested for HPV detection with
the patient’s permission, in the Department of Obstetrics and
Gynecology, The Catholic University of Korea. Cervical swabs were
o b t a i n e dw i t haC e r e x - B r u s h( P a p p e t e H, Wallach Surgical Devices,
Inc., Orange, CT.,USA). The brush was immediately rinsed in a vial of
PreservCytH solution (Cytyc Corpor., Boxborough, MA.,USA). To
isolate DNA, two millimeters of cell suspension was transferred to a 2-
ml reaction tube and washed twice by centrifugation at 14,000 rpm for
2 min, followed by removal of the supernatant and resuspension of the
pellet in 1 ml of phosphate-buffered saline. The pellet was resuspended
in 200 ml of phosphate-buffered saline and used for DNA isolation with
the Qiagen blood DNA minikit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions.
Plasmid clones
For the evaluation of specificity and cross hybridization of the
bead-based MPG method, plasmid clones of the following 20 HPV
Table 4. Total women with a different HPV test and a histological diagnosis.
High risk
HPV type HPV positives
Women with CIN2+ among
the HPV positives
Women with a histology
diagnosis
PPV for CIN2+
(95% CI)
16 105 50 64 78.1 (68.0–88.3)
18 31 9 18 50.0 (26.9–73.1)
31 15 3 6 50.0 (10.0–90.0)
33 7 4 5 80.0 (44.9–100.0)
35 10 1 2 50.0 (0.0–100.0)
39 16 0 9 0
45 3 0 0 -
51 19 1 7 14.3 (0.0–40.2)
52 25 2 13 15.4 (0.0–35.0)
53 38 1 15 6.7 (0.0–19.3)
56 20 0 8 0
58 31 5 11 45.5 (16.0–74.9)
59 4 0 2 0
66 9 1 6 16.7 (0.0–46.5)
68 9 1 4 25.0 (0.0–67.4)
total 342 78 170 45.9 (38.4–53.4)
doi:10.1371/journal.pone.0032259.t004
Table 5. Women .40 years of age with a different HPV test and a histological diagnosis.
High risk
HPV type HPV positives
Women with CIN2+ among
the HPV positives
Women with a histology
diagnosis
PPV for CIN2+
(95% CI)
16 36 25 31 80.6 (66.7–94.6)
18 13 6 10 60.0 (29.6–90.4)
31 4 3 3 100
33 4 2 3 66.7 (13.3–100)
35 4 1 2 50.0 (0.0–100)
39 3 0 2 0
45 1 0 0 -
51 8 2 8 25.0 (0.0–55.0)
52 6 1 6 16.7 (0.0–46.5)
53 13 0 13 0
56 4 0 4 0
58 13 5 10 50.0 (19.0–81.0)
59 2 0 2 0
66 5 1 5 20.0 (0.0–55.1)
68 4 1 2 50.0 (0.0–100)
total 120 47 101 46.5 (36.8–56.3)
doi:10.1371/journal.pone.0032259.t005
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55, 56, 58, 59, 66, 68 and 70.
Oligonucleotide probes for HPV genotyping
The type-specific oligonucleotide probes were designed for 20
different HPVs (15 high risk HPV types including 16, 18, 31, 33,
35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68 and 5 low risk HPV types
including 6, 11, 40, 55, 70) on the basis of the DNA sequences of
the viral L1 gene, which were obtained from the HPV database
(http://hpv-web.lanl.gov/) (Table S3). All probes had 59-amine
modification for bead coupling as well as 15 bp oligo-dT
sequences attached for hybridization flexibility.
Amplification of the L1 fragment and its labeling
Amplification of the L1 gene on 200 ng of genomic DNA
isolated from cervical samples was carried out with the
biotinylated PGMY09/11 primer set. PCR conditions were the
same as published in the PGMY 09/11 version [8]. For a positive
control, of the PCR, two primers were used for amplification of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sequences:
GAPDH F, 59-GAGTCAACGGATTTGGTCGT-39 for the
forward primer and GAPDH R, 59-TTGATTTTGGAGG-
CATCTCG-39 for the reverse primer. Since the copy number of
the GAPDH gene in the clinical sample was usually higher than
that of the HPV, the GAPDH primer concentration was reduced
to one fourth of the PGMY09/11 primer concentration. A
biotinylated primer set was used for one step PCR reaction. The
PCR components in 20 mL PCR mixture were 0.025 mM
biotinylated PGMY09/11 primer, 40 mM dATP, dGTP, dTTP
mixture, 10 mM biotin-11-dCTP (Invitrogen, Carlsbad, CA,
USA), 75 mM Tris HCl (pH 9.0), 20 mM MgCl2, 50 mM KCl,
20 mM (NH4)2SO4, and 1.5 U Taq polymerase (Biotools, Madrid,
Spain). A 5-min denaturation step at 94uC was followed by a 40-
cycle denaturation step at 94uC for 1 min, an annealing step at
53uC for 1 min and an elongation step at 72uC for 1 min.
Coupling of oligonucleotide probes to beads
The type-specific oligonucleotide probes were 59-amine mod-
ified and then were coupled to carboxylated beads (Luminex
Corp., Austin, TX, USA) through a carbodiimide base coupling
procedure. Preparation of the beads coupled with oligonucleotide
followed a procedure reported previously [12]. Each bead carrying
the type-specific oligonucleotide was finally mixed in equal
proportion. Here, this mixture is referred to as the bead mix.
Hybridization assay
Hybridization buffer (21 mLo f2 6EZway Hybrisol; Koma Co.,
Seoul, Korea) and 1 mL of HPV bead mix containing 6.75610
4
beads (2.5610
3 for each HPV type and control) were added to a
labeling tube containing the PCR product. The hybridization was
conducted as previously reported [12]. After hybridization, the
samples were transferred to a filter plate immediately and washed
three times with washing buffer (0.2 M NaCl, 0.1 M Tris, 0.08%
Triton X-100, pH 8.0) at room temperature. The beads were
resuspended for 15 min in 100 mL of streptavidin-R-phycoery-
thrin (Strep-PE; Molecular Probes, Eugene, OR, USA) and
analyzed for internal bead color and R-phycoerythrin receptor
fluorescence on a Luminex 100 analyzer. The median reporter
fluorescence intensity (MFI) of at least 100 beads was computed for
each bead set in the sample.
Sequencing
The amplified L1 gene with the PGMY09/11 primer set was
purified with the QIAquick PCR Purification Kit (Qiagen)
according to the manufacturer’s instructions. Sequencing was
performed using the BigDye Terminator v3.1 cycle sequencing kit
with AmpliTaq DNA polymerase (Applied Biosystems) according
to the protocols supplied by the manufacturer with type-specific
primers. The sequences obtained from the sequencing were
compared with the HPV sequences of known types using the basic
local alignment search tool from the NCBI website (http://www.
ncbi.nlm.nih.gov/BLAST).
Cutoff definition and statistical analysis
Reactions of the probes with the PCR products derived from
the PGMY09/11 PCR on 200 ng of HPV negative genomic DNA
was considered the background values. In this study, the HPV
negative genomic DNA was extracted from the human cervical
cancer cell line C33A. The background was calculated by the
mean value of 19 replicates and the cut-off value was 150 MFI,
which is slightly higher than the highest background of 135 MFI,
for all HPV probes. Agreement between the bead-based MPG
method and sequencing was assessed by the Cohen k statistic, with
values of 0.00 to 0.20 indicating poor agreement; 0.21 to 0.40, fair
agreement; 0.41 to 0.60, moderate agreement; 0.61 to 0.8,
substantial agreement; and 0.81 to 1.00 almost perfect agreement.
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